February 2016: SMC decisions

The Scottish Medicines Consortium has approved the following medicines for use in NHS Scotland for specific indications: fulvestrant (Faslodex; AstraZeneca); golimumab (Simponi; Merck Sharp and Dohme); guanfacine (Intuniv; Shire); panobinostat (Farydak; Novartis); and ulipristal acetate (Esmya; Gedeon Richter). 

Eculizumab (Soliris; Alexion), pixantrone (Pixuvri; CTI Life Sciences) and teduglutide (Revestive; NPS Pharma) have not been recommended for use.

Citation: The Salvadore DOI: 10.1211/PJ.2016.20200782

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.

  • Stockley's Drug Interactions Pocket Companion

    The 2016 pocket guide to drug interactions and their management, for the busy healthcare professional.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

вимакс форте купить в украине

недорогие препараты для повышения потенции у мужчин

Cialis sans ordonnance